These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 34959554)

  • 1. Inhibition of Viral Membrane Fusion by Peptides and Approaches to Peptide Design.
    Düzgüneş N; Fernandez-Fuentes N; Konopka K
    Pathogens; 2021 Dec; 10(12):. PubMed ID: 34959554
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations That Increase the Stability of the Postfusion gp41 Conformation of the HIV-1 Envelope Glycoprotein Are Selected by both an X4 and R5 HIV-1 Virus To Escape Fusion Inhibitors Corresponding to Heptad Repeat 1 of gp41, but the gp120 Adaptive Mutations Differ between the Two Viruses.
    Zhuang M; Vassell R; Yuan C; Keller PW; Ling H; Wang W; Weiss CD
    J Virol; 2019 Jun; 93(11):. PubMed ID: 30894471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Viral Entry Inhibitors Targeting Six-Helical Bundle Core against Highly Pathogenic Enveloped Viruses with Class I Fusion Proteins.
    Pu J; Zhou JT; Liu P; Yu F; He X; Lu L; Jiang S
    Curr Med Chem; 2022; 29(4):700-718. PubMed ID: 33992055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of the Fusion Peptide-Containing Region in Betacoronavirus Spike Glycoproteins.
    Ou X; Zheng W; Shan Y; Mu Z; Dominguez SR; Holmes KV; Qian Z
    J Virol; 2016 Jun; 90(12):5586-5600. PubMed ID: 27030273
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 gp41 Residues Modulate CD4-Induced Conformational Changes in the Envelope Glycoprotein and Evolution of a Relaxed Conformation of gp120.
    Keller PW; Morrison O; Vassell R; Weiss CD
    J Virol; 2018 Aug; 92(16):. PubMed ID: 29875245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Template-based coiled-coil antigens elicit neutralizing antibodies to the SARS-coronavirus.
    Tripet B; Kao DJ; Jeffers SA; Holmes KV; Hodges RS
    J Struct Biol; 2006 Aug; 155(2):176-94. PubMed ID: 16697221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors.
    Liu S; Xiao G; Chen Y; He Y; Niu J; Escalante CR; Xiong H; Farmar J; Debnath AK; Tien P; Jiang S
    Lancet; 2004 Mar; 363(9413):938-47. PubMed ID: 15043961
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins.
    Si Z; Madani N; Cox JM; Chruma JJ; Klein JC; Schön A; Phan N; Wang L; Biorn AC; Cocklin S; Chaiken I; Freire E; Smith AB; Sodroski JG
    Proc Natl Acad Sci U S A; 2004 Apr; 101(14):5036-41. PubMed ID: 15051887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
    Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
    J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early steps of HIV-1 fusion define the sensitivity to inhibitory peptides that block 6-helix bundle formation.
    Miyauchi K; Kozlov MM; Melikyan GB
    PLoS Pathog; 2009 Sep; 5(9):e1000585. PubMed ID: 19763181
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus (HIV) gp41 escape mutants: cross-resistance to peptide inhibitors of HIV fusion and altered receptor activation of gp120.
    Desmezieres E; Gupta N; Vassell R; He Y; Peden K; Sirota L; Yang Z; Wingfield P; Weiss CD
    J Virol; 2005 Apr; 79(8):4774-81. PubMed ID: 15795263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The stability of the intact envelope glycoproteins is a major determinant of sensitivity of HIV/SIV to peptidic fusion inhibitors.
    Gallo SA; Sackett K; Rawat SS; Shai Y; Blumenthal R
    J Mol Biol; 2004 Jun; 340(1):9-14. PubMed ID: 15184018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fusion core structure of the severe acute respiratory syndrome coronavirus (SARS-CoV): in search of potent SARS-CoV entry inhibitors.
    Chu LH; Chan SH; Tsai SN; Wang Y; Cheng CH; Wong KB; Waye MM; Ngai SM
    J Cell Biochem; 2008 Aug; 104(6):2335-47. PubMed ID: 18442051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanomolar inhibition of SARS-CoV-2 infection by an unmodified peptide targeting the pre-hairpin intermediate of the spike protein.
    Yang K; Wang C; Kreutzberger AJB; Ojha R; Kuivanen S; Couoh-Cardel S; Muratcioglu S; Eisen TJ; White KI; Held RG; Subramanian S; Marcus K; Pfuetzner RA; Esquivies L; Doyle CA; Kuriyan J; Vapalahti O; Balistreri G; Kirchhausen T; Brunger AT
    bioRxiv; 2022 Aug; ():. PubMed ID: 35982670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins.
    Steffen I; Pöhlmann S
    Curr Pharm Des; 2010; 16(9):1143-58. PubMed ID: 20030613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Why are HIV-1 fusion inhibitors not effective against SARS-CoV? Biophysical evaluation of molecular interactions.
    Veiga S; Yuan Y; Li X; Santos NC; Liu G; Castanho MA
    Biochim Biophys Acta; 2006 Jan; 1760(1):55-61. PubMed ID: 16290276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An antibody that blocks human T-cell leukemia virus type 1 six-helix-bundle formation in vitro identified by a novel assay for inhibitors of envelope function.
    Mirsaliotis A; Nurkiyanova K; Lamb D; Kuo CS; Brighty DW
    J Gen Virol; 2007 Feb; 88(Pt 2):660-669. PubMed ID: 17251585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.
    Zhuang M; Wang W; De Feo CJ; Vassell R; Weiss CD
    J Biol Chem; 2012 Mar; 287(11):8297-309. PubMed ID: 22235115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
    Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-1 gp41 six-helix bundle formation occurs rapidly after the engagement of gp120 by CXCR4 in the HIV-1 Env-mediated fusion process.
    Gallo SA; Puri A; Blumenthal R
    Biochemistry; 2001 Oct; 40(41):12231-6. PubMed ID: 11591141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.